These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23296753)

  • 1. Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom.
    Gordon J; Evans M; McEwan P; Bain S; Vora J
    Diabetes Ther; 2013 Jun; 4(1):51-66. PubMed ID: 23296753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective.
    Ponomareva E; Schmerold L; Sss S; Preblick R; Park S; Wilson L; Revel A
    J Med Econ; 2023; 26(1):1469-1478. PubMed ID: 37916295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
    Pollock RF; Curtis BH; Smith-Palmer J; Valentine WJ
    Adv Ther; 2012 Dec; 29(12):1051-66. PubMed ID: 23179373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia.
    Elsisi G; Ezzat M; Ramadan M
    J Health Econ Outcomes Res; 2023; 10(2):23-29. PubMed ID: 37600505
    [No Abstract]   [Full Text] [Related]  

  • 7. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses.
    McGlone ER; Carey I; Veličković V; Chana P; Mahawar K; Batterham RL; Hopkins J; Walton P; Kinsman R; Byrne J; Somers S; Kerrigan D; Menon V; Borg C; Ahmed A; Sgromo B; Cheruvu C; Bano G; Leonard C; Thom H; le Roux CW; Reddy M; Welbourn R; Small P; Khan OA
    PLoS Med; 2020 Dec; 17(12):e1003228. PubMed ID: 33285553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
    Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2019; 19(8):1-108. PubMed ID: 31942227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.
    Cummins E; Royle P; Snaith A; Greene A; Robertson L; McIntyre L; Waugh N
    Health Technol Assess; 2010 Feb; 14(11):iii-iv, xi-xvi, 1-181. PubMed ID: 20223123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
    Weatherall J; Bloudek L; Buchs S
    Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK.
    Thalange N; Gundgaard J; Parekh W; Tutkunkardas D
    BMJ Open Diabetes Res Care; 2019; 7(1):e000664. PubMed ID: 31543973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
    Ren H; Berry S; Malkin SJP; Hunt B; Bain S
    BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.